Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

Abstract Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis was conducted using clinical data of Japanese patien...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2022-01-01
coleção:	BMC Cancer
Assuntos:	unresectable pancreatic cancer nomogram prognosis overall survival chemotherapy
Acesso em linha:	https://doi.org/10.1186/s12885-021-09139-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!